Evrofarma SA (ATH:EVROF)

Evrofarma Statistics

Total Valuation

Evrofarma has a market cap or net worth of EUR 51.55 million. The enterprise value is 62.76 million.

Market Cap	51.55M
Enterprise Value	62.76M

Important Dates

The next estimated earnings date is Thursday, April 9, 2026.

Earnings Date	Apr 9, 2026
Ex-Dividend Date	Aug 19, 2025

Share Statistics

Evrofarma has 13.67 million shares outstanding.

Current Share Class	13.67M
Shares Outstanding	13.67M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	72.74%
Owned by Institutions (%)	n/a
Float	3.73M

Valuation Ratios

The trailing PE ratio is 23.58.

PE Ratio	23.58
Forward PE	n/a
PS Ratio	1.13
PB Ratio	2.89
P/TBV Ratio	2.91
P/FCF Ratio	12.49
P/OCF Ratio	9.63
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.45, with an EV/FCF ratio of 15.21.

EV / Earnings	27.52
EV / Sales	1.34
EV / EBITDA	11.45
EV / EBIT	16.74
EV / FCF	15.21

Financial Position

The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.95.

Current Ratio	0.97
Quick Ratio	0.59
Debt / Equity	0.95
Debt / EBITDA	2.87
Debt / FCF	4.11
Interest Coverage	3.42

Financial Efficiency

Return on equity (ROE) is 13.39% and return on invested capital (ROIC) is 10.24%.

Return on Equity (ROE)	13.39%
Return on Assets (ROA)	5.34%
Return on Invested Capital (ROIC)	10.24%
Return on Capital Employed (ROCE)	13.61%
Weighted Average Cost of Capital (WACC)	7.74%
Revenue Per Employee	275,416
Profits Per Employee	13,735
Employee Count	210
Asset Turnover	0.96
Inventory Turnover	5.36

Taxes

In the past 12 months, Evrofarma has paid 608,000 in taxes.

Income Tax	608,000
Effective Tax Rate	21.05%

Stock Price Statistics

The stock price has increased by +100.53% in the last 52 weeks. The beta is 0.77, so Evrofarma's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+100.53%
50-Day Moving Average	3.42
200-Day Moving Average	2.63
Relative Strength Index (RSI)	57.30
Average Volume (20 Days)	6,138

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evrofarma had revenue of EUR 45.72 million and earned 2.28 million in profits.

Revenue	45.72M
Gross Profit	9.23M
Operating Income	4.08M
Pretax Income	2.89M
Net Income	2.28M
EBITDA	5.85M
EBIT	4.08M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 3.32 million in cash and 16.95 million in debt, with a net cash position of -13.63 million or -1.00 per share.

Cash & Cash Equivalents	3.32M
Total Debt	16.95M
Net Cash	-13.63M
Net Cash Per Share	-1.00
Equity (Book Value)	17.83M
Book Value Per Share	n/a
Working Capital	-461,000

Cash Flow

In the last 12 months, operating cash flow was 5.35 million and capital expenditures -1.23 million, giving a free cash flow of 4.13 million.

Operating Cash Flow	5.35M
Capital Expenditures	-1.23M
Free Cash Flow	4.13M
FCF Per Share	0.30

Margins

Gross margin is 20.20%, with operating and profit margins of 8.92% and 4.99%.

Gross Margin	20.20%
Operating Margin	8.92%
Pretax Margin	6.32%
Profit Margin	4.99%
EBITDA Margin	12.79%
EBIT Margin	8.92%
FCF Margin	9.03%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 1.35%.

Dividend Per Share	0.05
Dividend Yield	1.35%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	29.82%
Buyback Yield	n/a
Shareholder Yield	1.35%
Earnings Yield	4.42%
FCF Yield	8.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 26, 2001. It was a forward split with a ratio of 2.

Last Split Date	Jul 26, 2001
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	7